Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product aids in lung function by reducing surface tension, improving oxygenation, and supporting breathing. Manufactured by Chiesi Farmaceutici S.P.A., it is designed for endotracheal administration.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs lack sufficient surfactant, a substance that keeps the air sacs open. By administering Curosurf, healthcare providers aim to improve lung function and breathing. The therapy is administered directly into the lungs via an endotracheal tube, providing immediate support to infants struggling with breathing difficulties.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce surface tension and improve oxygenation. This can lead to better lung expansion and easier breathing for premature infants. The effects are typically observed soon after administration, providing crucial support during a critical period of development.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. It is essential to follow proper handling and storage guidelines to maintain its efficacy. As with any medical treatment, monitoring for any adverse reactions is important, and healthcare providers should be informed of any pre-existing conditions or allergies.

Curosurf is generally used as a standalone therapy and may not interact with other medications. However, it is important to inform healthcare providers of any other treatments the infant is receiving to ensure compatibility and safety. Always consult with a healthcare professional for personalized advice.